Establishment Labs Holdings: Innovating Women's Health with Advanced Medical Technologies

Establishment Labs: Pioneering Innovations in Women's Health and Aesthetics

Establishment Labs Holdings Inc. continues to solidify its leadership position within the global medical technology landscape, particularly in the realm of women’s health concerning breast aesthetics and reconstruction. The company prepares to announce its financial results for the quarter ending December 31, 2024, on February 26, 2025. This announcement comes alongside a scheduled conference call aimed at discussing these results, reflecting the company’s commitment to transparency and engagement with its stakeholders. The call will be accessible to participants both in the U.S. and internationally, showcasing the company's global reach and investor-focused approach.

Since its inception, Establishment Labs has delivered over four million Motiva® devices, setting a new standard for safety and patient satisfaction in breast enhancement and reconstruction procedures. The company’s product portfolio includes innovative solutions such as the Mia Femtech® for breast harmonization and the Preservé™ system, which employs breast tissue preservation techniques for augmentation and revision. Particularly noteworthy is the Motiva Flora® tissue expander, which integrates radio-frequency technology and is MRI conditional, enhancing the reconstruction process for cancer survivors. These advancements illustrate Establishment Labs' dedication to improving patient outcomes through cutting-edge technology.

In addition to its established offerings, Establishment Labs is actively driving research and development for future innovations. The GEM® system, which is currently undergoing a pivotal study, focuses on gluteal ergonomic modeling, while the Zensor™ platform, featuring the Zenº™ biosensor, aims to provide continuous monitoring of core breast temperature—representing significant progress in patient care and post-operative monitoring. With over 200 patent applications filed globally and more than 100 scientific publications in peer-reviewed journals, Establishment Labs’ commitment to innovation is evident. The company operates in compliance with stringent regulatory standards, manufacturing its products in two facilities in Costa Rica, certified under ISO13485:2024 and FDA guidelines.

Establishment Labs not only emphasizes technological advancement but also prioritizes the safety and satisfaction of its patients. By focusing on minimally invasive solutions and pioneering research, the company plays a crucial role in enhancing women's health and wellness. Their commitment to quality and safety, combined with an impressive track record of innovation, positions Establishment Labs as a key player in the medical technology industry. For more information about their offerings and ongoing studies, interested parties can visit their website at www.establishmentlabs.com.